Insider Selling: GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells $62,000.40 in Stock

GlycoMimetics, Inc. (NASDAQ:GLYC) major shareholder Public Equities L.P. Invus sold 258,335 shares of the stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $0.24, for a total transaction of $62,000.40. Following the sale, the insider now owns 8,330,729 shares of the company’s stock, valued at approximately $1,999,374.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Public Equities L.P. Invus also recently made the following trade(s):

• On Monday, July 29th, Public Equities L.P. Invus sold 363,949 shares of GlycoMimetics stock. The shares were sold at an average price of $0.24, for a total transaction of $87,347.76.

GlycoMimetics Stock Performance

GLYC stock opened at $0.22 on Friday. The firm has a 50 day moving average of $0.27 and a 200-day moving average of $1.65. GlycoMimetics, Inc. has a 12-month low of $0.20 and a 12-month high of $3.53. The company has a market cap of $13.92 million, a price-to-earnings ratio of -0.37 and a beta of 2.19.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sell-side analysts forecast that GlycoMimetics, Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GlycoMimetics

An institutional investor recently raised its position in GlycoMimetics stock. Vanguard Group Inc. grew its stake in shares of GlycoMimetics, Inc. (NASDAQ:GLYC) by 14.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,761,981 shares of the biotechnology company’s stock after acquiring an additional 340,112 shares during the period. Vanguard Group Inc. owned about 4.29% of GlycoMimetics worth $8,286,000 at the end of the most recent reporting period. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on GLYC. HC Wainwright restated a “neutral” rating on shares of GlycoMimetics in a research report on Tuesday, June 4th. Capital One Financial downgraded shares of GlycoMimetics from an “overweight” rating to an “equal weight” rating in a research report on Monday, May 6th. StockNews.com began coverage on shares of GlycoMimetics in a research report on Friday. They issued a “sell” rating for the company. Finally, TD Cowen downgraded shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research report on Friday, July 26th.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.